Regulatory Approvals

FDA Approves Subcutaneous Induction for Skyrizi in Crohn’s Disease

By

Regulatory Approvals — FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease  Pharmaceutical Executive

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 23, 2026.

By

Related Post

Regulatory Approvals

FDA approves GSK’s functional cure for hepatitis B

Regulatory Approvals

Edwards wins FDA approval for tricuspid valve repair device

Regulatory Approvals

FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D

Financial News For All

Labor

UPDATE: CSU faculty union seeks strike authority as contract talks stall

Labor

Chili’s workers’ lawsuit looks to strike New York state’s lower wage for tipped workers

Regulatory Approvals

FDA approves GSK’s functional cure for hepatitis B

Regulatory Approvals

FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D